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Abstract
Heparin induced thrombocytopenia (HIT) is a life-threatening disorder which diagnosis depends on laboratory evaluation. The objective of this re-
port is to present the impact of different laboratory methods for HIT detection on the diagnostic evaluation process. In this case, a 78-year old female 
patient previously diagnosed with monoclonal gammopathy of undetermined significance (MGUS) was administered with heparin for pulmonary 
embolism treatment. Patient’s initial diagnostic work-up (determination of platelet count and prothrombin time measurement for monitoring of 
pharmacotherapy) was followed by the clinical estimation of HIT likelihood by “4Ts” score, two immunoassays (ID-PaGIA Heparin/PF4 Antibody Test 
and ELISA PF4 IgG assay) and one functional test called high-performance liquid chromatography serotonin release assay (HPLC-SRA). The result of 
“4Ts” score indicated a low likelihood of HIT but persistent thrombocytopenia that appeared days after discontinuation of heparin therapy suggested 
delayed-onset HIT. Both immunoassays were positive for presence of HIT-autoantibodies, while the functional HPLC-SRA was negative. Since diffe-
rent methods gave opposing results, their interpretation required great attention. In comparison to the HPLC-SRA, immunoassays are prone to the 
analytical interferences associated with the presence of non-specific antibodies, which may lead to false positive results. In this case, where the pa-
tient is known to produce antibodies of undetermined significance, HIT was ruled out as the possible cause of persistent thrombocytopenia primarily 
due to the negative result of HPLC-SRA, which is not prone to this type of interferences, but also due to the low “4Ts” clinical score.
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Heparin-induced thrombocytopenia type II (HIT) 
is a rare, immune-mediated condition that may 
emerge in the course of heparin therapy or as a late 
response reaction. It is caused by an autoantibody 
directed against heparin/platelet factor 4 (PF4) 
complex. New heparin/PF4/antibody complex at-
taches to the platelet surface FCγIIa receptors caus-
ing platelet activation, aggregation and increased 
clearance that lead to serious thrombocytopenia 
(1-5). Simultaneously, platelet activation initiates 
the blood-coagulation cascades often resulting in 
the thrombotic events, which may be lethal. 
A straightforward, yet not definitive approach to 
the determination of the clinical likelihood of HIT 
relies on several scoring systems, among which 
“4Ts” and HIT Expert Probability (HEP) scores are 
the most frequently used. The “4Ts” score takes 
into account the magnitude of thrombocytopenia, 
timing of onset of thrombocytopenia, thrombosis 
and other causes of thrombocytopenia. On the 
other hand, HEP score considers the magnitude 
and timing of fall in platelet count, nadir platelet 
count, thrombosis, skin necrosis, acute systemic 
reaction, bleeding and other causes of thrombo-
cytopenia (2,6). Inconclusive scores are followed 
by laboratory HIT evaluation that includes immu-
noassays and/or tests of platelet function. In im-
munoassays, such as enzyme linked immunosorb-
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ent assay (ELISA), particle gel immunoassay (PaGIA) 
and particle immunofiltration assay (PIFA), HIT-au-
toantibodies bind to the PF4/heparin or similar 
complex attached to the solid phase or dissolved in 
the liquid phase (2-4,6,7). The ability of HIT-autoan-
tibody to activate healthy donor platelets in pres-
ence of heparin is the basis of functional tests like 
serotonin release assays (SRA) (C14-SRA, high per-
formance liquid chromatography (HPLC)-SRA, flow 
cytometry SRA) and platelet aggregation assays 
(heparin induced platelet activation assays (HIPA) 
and platelet aggregation test (PAT)) (2-4,6,7). 
Immunoassays are characterized by high sensitivi-
ty (89-97%) and high negative predictive value (> 
95%) but the tendency to nonspecific antibody 
binding lowers diagnostic specificity of HIT immu-
noassays to 80-90% (6-9). Potential false positive 
results can occur in conditions and diseases with 
the excessive production of antibodies, like in au-
toimmune diseases and some hematologic disor-
ders. Monoclonal gammopathy of undetermined 
significance (MGUS) is such a condition, where el-
evated production of monoclonal antibodies by 
plasma cells may lead to cross-reactions with the 
immunoassay test components (1). Regarding that, 
Nazi et al. presented results of HIT testing in a large 
method comparison study, where 20.9% of sam-
ples were immunoassay positive, but functional 
test results were negative (10). In comparison to 
immunoassays, functional tests have higher speci-
ficity and sensitivity (both > 95%) since they de-
tect only a subset of antibodies that activate plate-
lets in heparin-dependent manner (6,7,11). The ex-
ception is PAT, the sensitivity of which is lower due 
to application of platelet rich plasma rather than 
washed platelets (6). The aim of this case report is to 
present the impact of different laboratory method-
ologies on the establishment of HIT diagnosis in the 
presence of MGUS. To the best of our knowledge, 
this is the first such case ever reported. 
Materials and methods
Subject
Here we present a case of a 78-year old female pa-
tient admitted to Emergency Department of Osi-
jek University Hospital (Osijek, Croatia) with the 
breathing difficulties. Her medical history included 
hypertension, diabetes mellitus type II, hyper-
uricemia, MGUS IgG lambda (λ) type. Computer 
tomography scan of the patient’s thorax showed 
pulmonary embolism that was treated by low mo-
lecular weight heparin (LMWH). LMWH therapy 
has been administrated from the day of admission 
(day 1) to the 10th day of hospitalization. On the 
4th day of hospitalization, oral anticoagulant ther-
apy was introduced. After 13 days the patient was 
discharged from the hospital. She has been in-
structed to continue with the coumarin therapy. 
Two weeks later the patient was readmitted to 
Emergency Department of Osijek University Hos-
pital with mouth bleeding and hematomas on her 
abdomen, arms and legs. This time the patient was 
diagnosed with severe thrombocytopenia and 
oral anticoagulant overdose which were managed 
at admission by a dose of vitamin K, platelet con-
centrate and corticosteroids. The bleeding 
stopped. Due to severe thrombocytopenia and a 
history of recent heparin therapy, the delayed on-
set of HIT was suspected. All anticoagulant thera-
py was immediately ceased and new thrombotic 
incident did not occur. As the patient already suf-
fered from thrombocytopenia caused by angio-
tensin-converting-enzyme inhibitor approximate-
ly one year before this event and then responded 
well to corticosteroid therapy, the same therapy 
was applied on day 2 during the second hospitali-
zation. However, 14 days later, the thrombocytope-
nia persisted and immunoglobulin and rituximab 
therapy was started. After 37 days, patient was dis-
charged with persistent thrombocytopenia. 
Signed informed consent was obtained from the 
patient. Diagnostic work-up was performed in ac-
cordance with the Declaration of Helsinki.
Sample collection and routine evaluation 
Patient’s whole blood samples and plasma sam-
ples were collected in K3-EDTA tubes and tubes 
containing 0.105 M sodium citrate, respectively 
(Becton Dickinson, Franklin Lakes, USA). Through-
out patient’s first and second hospitalization plate-
let count was determined by the Sysmex 2000XN 
automated haematology analyser (Sysmex Corpo-
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ration, Kobe, Japan) while the prothrombin time 
was measured by the BCS XP automated coagula-
tion analyser (Siemens Healthcare, Erlangen, Ger-
many). On day 2 of the second hospitalization pa-
tient’s blood for HIT-autoantibodies detection was 
sampled in tubes containing no additives (Becton 
Dickinson, Franklin Lakes, USA). The diagnostic al-
gorithm for the evaluation of suspected HIT was 
performed during the second hospitalization in 
accordance with Farm et al. (11). On the day after 
admission (day 2), clinical likelihood of HIT was as-
sessed by the clinician according to the “4Ts” score 
questionnaire (2,6). A total score of 0-3 is associat-
ed with low likelihood, 4-5 is associated with me-
dium and 6-8 stands for a high clinical likelihood 
of HIT. Score calculation and two immunoassays 
were performed on the same day, while the func-
tional test was performed on day 4.
Gel agglutination assay 
Gel agglutination assay was the first immunoassay 
used for the diagnostic evaluation of our subject. 
Rapid particle gel agglutination immunoassay, 
namely ID-PaGIA Heparin/PF4 Antibody Test (Dia-
med SA, Cressier sur Morat, Switzerland) is a quali-
tative/semi-quantitative test that uses high densi-
ty polymeric particles coated with the PF4/heparin 
complex deposited on a gel matrix. According to 
the manufacturer, positive reaction can be graded 
as: complete agglutination on the top of the gel 
(grade 4+); strong agglutination with agglutinates 
distributed within upper part of the gel (grade 3+); 
partial agglutination when some particles reach 
the bottom of the microtube with agglutinates 
still visible in the upper part of the gel (grade 2+), 
agglutination throughout the gel (grade 1+ to 2+). 
The lesser agglutinations are considered as doubt-
ful reactions. In the absence of HIT-autoantibodies 
i.e. negative reaction, all particles are compacted 
at the bottom of the test microtube, otherwise the 
test is considered positive or doubtful. The test 
performance is described in Pouplard et al. (12). 
PF4 IgG ELISA
Gel agglutination assay was followed by the PF4 
IgG ELISA. Qualitative/semi-quantitative ELISA PF4 
IgG assay (Immucor GTI Diagnostics, Waukesha, 
USA) uses microwells coated with polyvinyl sul-
fonate (PVS) complexed with PF4. According to the 
manufacturer, test results showing optical density 
(OD) values equal or greater than 0.400 are regard-
ed as positive for presence of HIT-autoantibodies. 
The test was performed according to the manufac-
turer instructions described in Whitlatch et al. (13). 
HPLC-SRA assay
A functional test, in this case HPLC-SRA, was used 
for confirmation of HIT diagnosis. In the presence 
of HIT-autoantibodies, platelets undergo activa-
tion and degranulation followed by the serotonin 
release. Platelets were acquired from four donors 
with 0 negative blood type and platelet concen-
trate was prepared in house in accordance with 
the European Directorate for the Quality of Medi-
cines and Healthcare good practice guidelines (14). 
Platelet count and mean platelet volume (MPV) of 
unwashed concentrate were determined by the 
Sysmex 2000XN automated haematology analyser 
(Sysmex Corporation, Kobe, Japan). Platelet wash-
ing was done according to the procedure pro-
posed by Debeljak (15). After washing, platelet 
count and MPV were determined again. The sys-
tem suitability criteria were platelet count in the 
range of 250-450 x109/L and MPV alteration less 
than 10% of its initial value. Positive and negative 
control samples and patient’s blank and probe 
samples were prepared according to Koch et al. 
(Figure 1) (16).
Commercial IVD ClinRep HPLC Serotonin in Plasma 
validated kit (Recipe Chemicals + Instruments 
GmbH, Munich, Germany) was used for quantifica-
tion of the released serotonin (17). The measure-
ment was conducted using Shimadzu Class VP 10 
series (Shimadzu, Kyoto, Japan) HPLC instrument 
equipped with the electrochemical detector (ECD) 
CLC 100 (Chromsystems, Gräfelfing, Germany). Ser-
otonin standard, internal standard solutions and 
analytical column were acquired from the kit man-
ufacturer. Sample injection volume was set to 10 
µL, flow rate was set to 1.0 mL/min, run time was 
set to 8 minutes and applied voltage on ECD was 
set to 0.6 V. The exact procedure is described else-
where (15). 
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Percentage of serotonin release (SR) from func-
tional HPLC-SRA was calculated according to the 
following equation: SR = PR / PCR x 100%, where PR 
stands for serotonin peak area and internal stand-
ard peak area ratio for patient’s probe. PCR stands 
for serotonin peak area and internal standard peak 
area ratio for positive control. If SR exceeds 20%, 
the patient is considered positive for presence of 
HIT-autoantibodies.
Results 
Platelet counts and prothrombin times deter-
mined during the first and the second hospitaliza-
tion are given in Tables 1 and 2. The patient’s “4Ts” 
score of 3 points signifies low likelihood of HIT, 
where 1 point was accounted for the platelet 
count fall 30-50% or platelet nadir 10-19 x109/L, 1 
point was accounted for the onset that took place 
after day 10 of therapy (prior heparin exposure 30-
100 days ago) and 1 point was accounted for other 
possible causes for thrombocytopenia.
According to the rapid assay ID-PaGIA Heparin/
PF4 Antibody Test patient’s serum was positive for 
HIT-autoantibodies (grade 3+). ELISA PF4/IgG As-
say also gave positive result: OD value was 1.28. In 
contrast to the immunoassays, functional HPLC-
SRA was negative. Serotonin release for the pa-
tient’s sample calculated according to the equa-
tion was 1.5% (Figure 2).
Discussion
HIT is strongly suspected in patients on heparin 
therapy if platelet count drops under 150 x109/L 
(median platelet count nadir is about 55 x109/L) 
and if platelet count declines for more than 50% 
from its initial value (2,3). During pharmacothera-
py with the LMWH, patient’s platelet count was 
within reference range (Table 1), but the platelet 
count decrease and the coumarin overdose were 
registered 14 days after discontinuation of therapy 
(Table 2). Although “4T”s score indicated low likeli-
hood of HIT, low platelet count was consistent 
with delayed-onset HIT. According to the litera-
Table 1. Pharmacotherapy, platelet counts and prothrombin times during first hospitalization
Day 1 Day 2 Day 3 Day 7 Day 8 Day 10 Day 13 Reference interval
Platelet count (x109/L) 279 220 326 261 247 224 NA 158 - 424
Prothrombin time ratio (%) NA NA 0.71 0.18 0.34 0.30 0.34 0.70 – 1.27
Prothrombin time INR NA NA 1.17 3.21 1.97 2.16 1.98 /
LMWH therapy + + + + + + - /
Cumarin anticoagulant therapy - - - + + + + /
LMWH – low molecular weight heparin. NA - not available. (+) - Present. (-) - Absent.
Table 2. Pharmacotherapy, platelet counts and prothrombin times during second hospitalization
Day 1 Day 3 Day 4 Day 5 Day 19 Day 34 Day 37 Reference interval
Platelet count (x109/L) 13 14 12 8 24 19 22 158 - 424
Prothrombin time ratio (%) 0.06 0.81 0.75 0.89 1.14 1.01 NA 0.70 – 1.27
Prothrombin time INR > 6.0 1.12 1.15 1.07 0.95 0.99 NA /
LMWH therapy - - - - - - - /
Cumarin anticoagulant therapy + - - - - - - /
LMWH – low molecular weight heparin. NA - not available. (+) - Present. (-) - Absent.
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Figure 2. Serotonin and internal standard (ISTD) peak in HPLC-
SRA. The solid line corresponds to the patient’s probe, the dot-
ted line to the positive control and grey line to the blank probe.
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ture, sera from patients with delayed-onset are 
usually strongly reactive in the immunoassays and 
activate platelets in SRA even in the absence of 
pharmacologic heparin concentrations (18,19). 
With that in mind, we performed a laboratory 
evaluation without which possible HIT diagnosis 
cannot be confirmed or rejected.
The first test we used was gel agglutination test, 
which is widely available due to its low cost, sim-
plicity of performance and low time consumption. 
ID PaGIA test was highly positive (grade 3+), but 
the interpretation of test result is susceptible to 
subjective reading. To improve diagnostic certain-
ty, we performed ELISA IgG, a test characterized 
by automated, i.e. less subjective, measurement. 
The OD value of 1.28 also suggested presence of 
HIT-autoantibodies and was consistent with de-
layed-onset HIT. In compliance with our patient’s 
immunoassay test results and published research 
results we expected moderately strong donor 
platelet activation with patient’s sera in HPLC-SRA 
test (20). Contrary to that, the percentage of re-
leased serotonin was low and diagnosis of HIT was 
excluded. 
All immunoassays share a common interference in 
the form of cross-reactivity and unspecific binding 
that may lead to the false positive results (21). Pres-
ence of the MGUS IgG λ endogenous antibodies in 
patient’s serum raises a suspicion that these anti-
bodies non-specifically bind to the PF4/heparin in 
gel agglutination assay and to the PF4/PVS in ELI-
SA causing positive reaction in both tests. The 
manufacturer of the ELISA PF4 IgG assay clearly 
states that the presence of immune complexes or 
other immunoglobulin aggregates in patient’s 
sample may cause an increased nonspecific bind-
ing leading to the false-positive results. Along with 
that, the literature describes several cases where 
HIT was misdiagnosed or over diagnosed due to 
interferences and cross-reactivity in immunoas-
says. For example, Hron et al. described two cases 
where immunoassays were false positive for the 
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presence of HIT-autoantibodies (22). In the first 
case, an elderly patient developed alloantibodies 
to human platelet antigen-1a as a consequence of 
blood transfusion which led to thrombocytopenia 
and post-transfusion purpura. In the second case, 
an elderly patient developed the piperacilin-de-
pendent platelet antibodies and nonpathogenic 
heparin/PF4 IgA antibodies, which led to the drug-
induced thrombocytopenia after pneumonia 
treatment with piperacilin/tazobactam. The func-
tional test in the second case was negative. More-
over, Alpert et al. found the prevalence of heparin/
PF4 antibodies ranging between 4 and 15% in pa-
tients with antiphospholipid syndrome and sys-
temic lupus erythematosus, respectively, often in 
the absence of clinical HIT or recent heparin expo-
sure (23). As previous cases demonstrate, leaning 
on positive immunoassay alone can lead to a 
wrong suspicion about HIT and potential use of 
other anticoagulant drugs that can cause bleeding 
and additional healthcare costs (24-26). For that 
and similar reasons samples positive for HIT-au-
toantibodies in immunoassays should be evaluat-
ed by the functional tests.
HPLC-SRA is a modified version of the gold stand-
ard SRA-14C test but it does not require usage of 
radioactive material. The test has its own disad-
vantages like the requirement for the expensive 
equipment, requirement for a high level of exper-
tise and the long duration of sample preparation. 
Other limitations of the functional tests include se-
lection of donor platelets due to their significant 
interindividual variability in activation responsive-
ness (4,27) and non-standardized analysis of sero-
tonin release which is, in this case, an in-house so-
lution. As HPLC-SRA test is characterized by con-
siderably higher sensitivity and specificity than im-
munoassays, it served as a definitive test in this 
study. To recapitulate, the correct sequence of HIT 
diagnostic evaluation should follow the these 
steps: 1) assessment of the HIT clinical likelihood 
with the “4Ts” or other score questionnaire, 2) 
screening for possible HIT autoantibodies with ac-
cessible immunoassays, and 3) application of the 
HPLC-SRA or other highly specific assay, when the 
immunoassay results are positive or doubtful, for 
conformation or rejection of the HIT.
Based on HPLC-SRA, HIT has been excluded as an 
unlikely diagnosis but the cause of thrombocyto-
penia in this patient remained unknown. As shown 
in Table 2, the thrombocytopenia was still present 
after discontinuation of anticoagulant therapy, 
which leads to suspicion of immune thrombocyto-
penia, a state that may appear in patients with 
MGUS (28,29). However, absence of a serotonin 
peak in the blank probe in HPLC-SRA (Figure 2) 
demonstrates that the MGUS or antibodies other 
than HIT autoantibodies did not activate donor 
platelets. In addition, patient did not respond to 
corticosteroid, rituximab and immunoglobulin 
therapy during her second hospitalization, which 
implies that cause of the thrombocytopenia most 
likely, was not immune.
In conclusion, laboratory evaluation of HIT re-
quires great caution. In comparison with HPLC-
SRA, immunoassays are easier to perform but the 
presence of the non-specific antibodies may lead 
to the false positive results. Because of high sensi-
tivity and high negative predictive value, immuno-
assays are appropriate tools for ruling out the HIT 
diagnosis. HPLC-SRA and related functional tests 
are more sensitive and more specific. For the con-
firmation of HIT diagnosis and differential diagnos-
tics of thrombocytopenia described functional 
tests should be applied. 
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